Table 9.
Comparison of efficacy of the first-line combination of pemetrexed plus platinum followed by pemetrexed maintenance between Japanese Phase II studies and multinational Phase III studies
| Reference | Country | Phase | Patients | Treatment | PFS and OS from induction (M) |
|---|---|---|---|---|---|
| Ciuleanu et al29 (JMEN trial) |
Multi | R-p3 | 441 NSCLC, including 26% SQ | Plt-based doublet ×4 cycles | PFS 7.7 |
| → PEM maintenance | OS 16.5 | ||||
| Paz-Ares et al15,16 (PARAMOUNT trial) |
Multi | R-p3 | 359 non-SQ | CDDP + PEM ×4 cycles | PFS ND |
| → PEM maintenance | OS 16.9 | ||||
| Okamoto et al33 (JACAL trial) |
Japan | S-p2 | 109 non-SQ | CBDCA + PEM ×4 cycles | PFS 5.7 |
| → PEM maintenance | OS 20.2 | ||||
| Minami et al32 (OULCSG0902 trial) |
Japan | S-p2 | 34 non-SQ | CBDCA + PEM ×4 cycles | PFS 5.2 |
| → PEM maintenance | OS 23.3 | ||||
| Karayama et al31 | Japan | R-p2 | 26 non-SQ | CBDCA + PEM ×4 cycles | PFS 7.4 |
| → PEM maintenance | OS 25.0 |
Abbreviations: CBDCA, carboplatin; CDDP, cisplatin; M, month; Multi, multinational; ND, not described; NSCLC, non-small-cell lung cancer; OS, overall survival; PEM, pemetrexed; PFS, progression-free survival; Plt, platinum; R-p2, randomized phase II; R-p3, randomized phase III; S-p2, single-arm phase II; SQ, squamous cell carcinoma.